Just over £700mln was added to the value of Haleon PLC (LSE:HLN, NYSE:HLN), the consumer healthcare company that makes Advil and Sensodyne toothpaste, following an upbeat assessment of prospects.
In a trading statement, it told the market it expects organic revenue growth in 2023 to approach the high end of its projected 4%-6% range, driven by robust demand and the replenishment of respiratory health products amid a severe cold and flu season.
The GSK consumer healthcare spin-out maintained the remainder of its 2023 full-year outlook.
In the first 20 minutes of trade, the stock was changing hands for 351.6p, up 8p, or 2.3%.